Bay Colony Advisory Group Inc d b a Bay Colony Advisors lowered its stake in Crispr Therapeutics AG (NASDAQ:CRSP) by 20.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,950 shares of the company’s stock after selling 1,000 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Crispr Therapeutics were worth $231,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in CRSP. Bank of New York Mellon Corp lifted its holdings in Crispr Therapeutics by 116.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after purchasing an additional 17,810 shares during the last quarter. Northern Trust Corp raised its stake in shares of Crispr Therapeutics by 7.6% in the second quarter. Northern Trust Corp now owns 31,078 shares of the company’s stock worth $1,463,000 after acquiring an additional 2,188 shares during the last quarter. US Bancorp DE raised its stake in shares of Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Crispr Therapeutics by 26.1% in the second quarter. Vanguard Group Inc. now owns 81,159 shares of the company’s stock worth $3,822,000 after acquiring an additional 16,821 shares during the last quarter. Finally, Morgan Stanley raised its stake in shares of Crispr Therapeutics by 6.1% in the second quarter. Morgan Stanley now owns 284,984 shares of the company’s stock worth $13,423,000 after acquiring an additional 16,361 shares during the last quarter. 49.84% of the stock is currently owned by hedge funds and other institutional investors.
In other news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. In the last quarter, insiders have sold 48,618 shares of company stock valued at $3,230,760. 21.40% of the stock is owned by corporate insiders.
Shares of NASDAQ CRSP opened at $52.42 on Friday. Crispr Therapeutics AG has a 1-year low of $29.34 and a 1-year high of $74.00. The company has a 50-day moving average of $61.34 and a two-hundred day moving average of $52.68. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market cap of $2.99 billion, a PE ratio of -113.96 and a beta of 3.20.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The company had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. As a group, equities research analysts forecast that Crispr Therapeutics AG will post 0.65 earnings per share for the current year.
CRSP has been the subject of a number of research analyst reports. ValuEngine downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $104.00 target price on shares of Crispr Therapeutics in a research note on Monday, December 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 target price on shares of Crispr Therapeutics in a research note on Monday, December 23rd. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Finally, Roth Capital boosted their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $75.95.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Dividend
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.